Syndrome of Inappropriate Anti-diuretic Hormone (SIADH) in Non-small Cell Lung Cancer (NSCLC) Following Agent Orange Exposure: A Case Report
Abstract
We present the case of a 77-year-old male with a significant smoking history and prior Agent Orange exposure, who was admitted to the hospital multiple times with clinical and laboratory findings consistent with the syndrome of inappropriate anti-diuretic hormone (SIADH). The patient presented to the hospital on multiple occasions with symptoms and laboratory findings supportive of SIADH in the setting of malignancy. During his first visit, imaging studies demonstrated a right-sided pleural effusion, which was drained and sent for cytology and immunohistochemical staining studies. Following correction of his presenting hyponatremia, he was discharged with appropriate medications and follow-ups to discuss pleural fluid results. Three weeks later, he presented with similar symptoms, and the available pathology results of the pleural fluid specimen supported non-small cell lung cancer (NSCLC), likely adenocarcinoma. This report highlights a rare occurrence of SIADH in the setting of NSCLC and emphasizes the importance of considering atypical paraneoplastic syndrome presentations in patients with multifactorial hyponatremia. It also engages in a discussion of the pathophysiology, clinical presentation, and diagnostic approach to SIADH in the context of NSCLC.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.